Thus, we cannot exclude the possibility that obinutuzumab-binding FcγR on macrophages may be abrogating the benefits of TLR7 agonism.34 TLR agonists can potentially have a diverse role in activating the immune system and thus may enhance antibody-mediated tumor cell killing by numerous different mechanisms. Here, FCGR2A is linked to neoplasm.